StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences DTA by Year

DTA — Net operating loss and capital loss carryforwards ($M) ($M)

Gilead Sciences DTA: $266M in FY2025, down 7.6% from a year earlier.

Latest, FY2025
266
Period ended Dec 31, 2025
Change on a year earlier
-7.6%
288 in FY2024
History
12 years
Since FY2014
Sources
10
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-K Note 15.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDTA — Net operating loss and capital loss carryforwards ($M) ($M)Year on yearSource
FY2025Dec 31, 2025266-7.6%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 2024288-30.9%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 2023417-3.0%Form 10-K (filed 2025-02-28) ↗
FY2022Dec 31, 2022430+4.1%Form 10-K (filed 2024-02-23) ↗
FY2021Dec 31, 2021413-29.6%Form 10-K (filed 2023-02-22) ↗
FY2020Dec 31, 2020587+219.0%Form 10-K (filed 2022-02-23) ↗
FY2019Dec 31, 2019184-46.5%Form 10-K (filed 2021-02-25) ↗
FY2018Dec 31, 2018344+6.8%Form 10-K (filed 2019-02-26) ↗
FY2017Dec 31, 2017322+84.0%Form 10-K (filed 2019-02-26) ↗
FY2016Dec 31, 2016175-12.1%Form 10-K (filed 2018-02-27) ↗
FY2015Dec 31, 2015199-7.4%Form 10-K (filed 2017-02-27) ↗
FY2014Dec 31, 2014215–Form 10-K (filed 2016-02-24) ↗

Cite this data

StockData. (2026). Gilead Sciences DTA ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/dta-nol

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.